|
Showing 1 - 2 of
2 matches in All Departments
Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses
the major problem in cancer chemotherapy-its lack of selectivity.
Antibody delivery combined with the amplification provided by the
enzymatic activation of prodrugs enables selection to be made
between tumour and normal tissue. ADEPT offers a novel field of
opportunities in the therapy of systemic cancer and may be a major
advance for the treatment of solid tumours. This book is the first
to describe ADEPT in detail. Each chapter reviews an aspect of the
immunology, enzymology, biochemistry, chemistry, and cancer
chemotherapy which have been integrated into the ADEPT concept. An
additional chapter describes the related approach of gene-directed
enzyme prodrug therapy (GDEPT). This latter approach is still in
its infancy but ADEPT has entered the clinic. The initial clinical
studies with ADEPT are included and discussed in detail.
Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses
the major problem in cancer chemotherapy-its lack of selectivity.
Antibody delivery combined with the amplification provided by the
enzymatic activation of prodrugs enables selection to be made
between tumour and normal tissue. ADEPT offers a novel field of
opportunities in the therapy of systemic cancer and may be a major
advance for the treatment of solid tumours. This book is the first
to describe ADEPT in detail. Each chapter reviews an aspect of the
immunology, enzymology, biochemistry, chemistry, and cancer
chemotherapy which have been integrated into the ADEPT concept. An
additional chapter describes the related approach of gene-directed
enzyme prodrug therapy (GDEPT). This latter approach is still in
its infancy but ADEPT has entered the clinic. The initial clinical
studies with ADEPT are included and discussed in detail.
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.